Therapeutic interventions for hypertension in metabolic syndrome: A comprehensive approach

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 2, 2007, Pages 201-211

  Ganne, Sudha ^a   Arora, Surender K ^a   Karam, Jocelyne ^a   McFarlane, Samy I ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Hypertension; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SIMVASTATIN; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNINDEXED DRUG;

ADRENERGIC SYSTEM; AGING; ATHEROSCLEROSIS; BEHAVIOR MODIFICATION; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DRUG MECHANISM; EXERCISE; FREQUENCY ANALYSIS; GENETIC PREDISPOSITION; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; HYPERKALEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASODILATATION; WEIGHT REDUCTION;

AGE DISTRIBUTION; AGED; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; COMORBIDITY; DIET, REDUCING; DOGS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RATS; RISK ASSESSMENT; SEX DISTRIBUTION;

EID: 33947637246     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.2.201     Document Type: Review

References (73)

1. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26(11), 3153-3159 (2003).
2. Palaniappan L, Carnethon MR, Wang Y et al. Insulin Resistance Atherosclerosis Study. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 27(3), 788-793 (2004).
3. Eckel RH, Grundy SM, Zimmer PA. The metabolic syndrome. Lancet 365, 1415-1428 (2005).
4. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683-689 (2001).
5. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA 288, 2709-2716 (2002).
6. Girman CJ, Rhodes T, Mercuri M et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am. J. Cardiol. 93, 136-141 (2004).
7. Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110, 1245-1250 (2004).
8. Chobanian AV, Bakris GL, Black HR et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: the seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 289(19), 2560-2571 (2003).
9. McFarlane SI, Sica DA, Sowers JR. Stroke in patients with diabetes and hypertension. J. Clin. Hypertens. (Greenwich) 7(5), 286-292 (2005).
10. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N. Engl. J. Med. 334, 374-381 (1996).
11. Sowers JR, Epstein M, Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. Hypertension 26, 869-879 (1995).
12. Grunfeld B, Balzareti M, Romo M, Gimenez M, Gutman R. Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension 23(Suppl. 1), 112-115 (1994).
13. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 97, 2601-2610 (1996).
14. Sowers JR, Epstein M, Frolich ED. Diabetes, hypertension and cardiovascular disease: an update. Hypertension 37, 1053-1059 (2001).
15. El-Atat F, Aneja A, Mcfarlane S, Sowers J. Obesity and hypertension. Endocrinol. Metab. Clin. North Am. 32, 823-854 (2003).
16. Sowers JR. Insulin resistance and hypertension. Am. J. Physiol. Heart Circ. Physiol. 286, H1597-H1602 (2004).
17. Castro JP, El-Atat FA, McFarlane SI, Aneja A, Sowers JR. Cardiometabolic syndrome: pathophysiology and treatment. Curr. Hypertens. Rep. 5, 393-401 (2003).
18. Troisi RJ, Weiss ST, Parker DR, Sparrow D, Young JB, Landsberg L. Relation of obesity and diet to sympathetic nervous system activity. Hypertension 17, 669-677 (2001).
19. Tuck ML, Sowers J, Dornfield L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure plasma renin activity and plasma aldosterone level in obese patients. N. Engl. J. Med. 304, 930-933 (1981).
20. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am. J. Med. Sci. 324, 127-137 (2002).
21. Weyer C, Pratley RE, Snitker Spraul M, Ravussin E, Tataranni PA. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 36, 531-537 (2000).
22. Landsberg L, Young JB. Insulin-mediated glucose metabolism in the relationship between dietary intake and sympathetic nervous system activity. Int. J. Obes. 9(Suppl. 2), 63-68 (1985).
23. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J. Clin. Endocrinol. Metab. 86, 713-718 (2001).
24. Zhang R, Reisin E. Obesity-hypertension; the effects on cardiovascular and renal systems. Am. J. Hypertens. 13, 1308-1314 (2000).
25. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the CaptoPril Prevention Project (CAPPP) randomized trial. Lancet 353, 611-616 (1999).
26. Yusuf S, Gerstein H, Hoogwerf, B et al. Ramipril and the development of diabetes. JAMA 286, 1882-1885 (2001).
27. Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension study. J. Hypertens. 20, 1879-1886 (2002).
28. The DREAM trial investigators. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 355, 1551-1562 (2006).
29. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38, 884-890 (2001).
30. El-Atat F, McFarlane SI, Sowers JR. Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr. Hypertens. Rep. 6(3), 215-223 (2004).
31. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am. J. Cardiol. 91, 30H-37H (2003).
32. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109, 2054-2057 (2004).
33. Weiss R, Dufour S, Taksali SE et al. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 362, 951-957 (2003).
34. Bloomgarden ZT. Second World Congress on the insulin resistance syndrome: hypertension, cardiovascular disease, and treatment approaches. Diabetes Care. 28(8), 2073-2080 (2005).
35. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40, 609-611 (2002).
36. Furuhashi M, Ura N, Takizawa H et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J. Hypertens. 22, 1977-1982 (2004).
37. Garrison RJ, Kannel WB, Stokes J, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev. Med. 16, 234-251 (1987).
38. Lennie TA, Chung ML, Habash DL, Moser DK. Dietary fat intake and proinflammatory cytokine levels in patients with heart failure. J. Card. Fail. 11(8), 613-618 (2005).
39. Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. N. Engl. J. Med. 351(25), 2599-2610 (2004).
40. Sarzani R, Dessi-Fulgheri P, Salvi F et al. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J. Hypertens. 17, 1301-1305 (1999).
41. McFarlane SI, Sowers JR. Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J. Clin. Endocrinol. Metab. 88, 516-523 (2003).
42. Nannipieri M, Seghieri G, Catalano C, Prontera T, Baldi S, Ferrannini E. Defective regulation and action of atrial natriuretic peptide in type 2 diabetes. Horm. Metab. Res. 34, 265-270 (2002).
43. Vettor R, Mazzonetto P, Macor C et al. Effect of endogenous organic hyperinsulinemia on blood pressure and serum triglycerides. Eur. J. Clin. Invest. 24, 350-354 (1994).
44. Hall JE, Brands MW, Mizelle HL, Gaillard CA, Hildebrandt DA. Chronic intrarenal hyperinsulinemia does not cause hypertension. Am. J. Physiol. 260, F663-F669 (1991).
45. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52, 1210-1214 (2003).
46. Ford ES, Giles WE, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287(3), 356-359 (2002).
47. Olshansky SJ, Passaro DJ, Hershow RC et al. A potential decline in life expectancy in the United States in the 21st Century. N. Engl. J. Med. 352, 1138-1145 (2005).
48. Knowler WC, Barrett-Connor E, Fowler SE et al Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
49. Sacks FM, Svetkey LP, Vollmer WM et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet: DASH-Sodium Collaborative Research Group. N. Engl. J. Med. 344, 3-10 (2001).
50. Obarzanek E, Sacks FM, Vollmer WM et al. For the DASH Research Group. Effects on blood lipids of a blood pressure lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am. J. Clin. Nutr. 74, 80-89 (2001).
51. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis. 36, 646-661 (2000).
52. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16, 434-444 (1993).
53. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch. Intern. Med 153, 578-581 (1993).
54. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J. Am. Coll. Cardiol. 27, 1214-1218 (1996).
55. Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 277, 739-745 (1997).
56. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350, 757-764 (1997).
57. SHEP Cooperative Research Group, Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265, 3255-3264 (1991).
58. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
59. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomiscd trial against atenolol. Lancet 359, 995-1003 (2002).
60. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351, 1755-1762 (1998).
61. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 288, 2981-2997 (2002).
62. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. Br. Med. J. 317, 713-720 (1998).
63. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: The Collaborative Study Group. N. Engl. J. Med 329, 1456-1462 (1993).
64. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
65. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med 345, 851-860 (2001).
66. Sowers JR, Reed J. Clinical advisory treatment of hypertension in diabetes. J. Clin. Hypertens. 2, 132-133 (2000).
67. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253-259 (2000).
68. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 1004-1010 (2002).
69. Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens. 20, 1879-1886 (2002).
70. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368, 1096-1105 (2006).
71. Wing LMH, Reid CM, Ryan P et al, for Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-convertingenzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 348, 583-592 (2003).
72. Pyorala K, Ballantyne CM, Gumbiner B et al. The Scandinavian Simvastatin Survival Study (4S): reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Sinivastatin Survival Study (4S). Diabetes Care 27, 1735-1740 (2004).
73. Armitage J, Collins R. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials MRC/BHF Heart Protection Study. Heart 84(4), 57-360 (2000).